PubMed Health⌕ Search

Biomedical subjects

J E Mortimer

Publications and source records attributed to J E Mortimer.

24 records · Page 2Linked to original sources
PubMed1989

Myasthenia gravis and lymphoblastic lymphoma antiacetylcholine receptor antibody as a tumor marker--a case report.

This report documents an association between lymphoblastic lymphoma and myasthenia gravis. Elevation of acetylcholine receptor antibody titer was an unusual marker for the lymphoblastic lymphoma. Following chemotherapy all symptoms of myasthenia gravis resolved and the acetylcholine receptor antibody titer normalized. The patient remains in complete remission off all therapy 20 months since the diagnosis of myasthenia gravis was made and 12 months after chemotherapy for her lymphoma.

Antigens, Neoplasm↗
PubMed1989

Transcatheter therapy for malignant neoplasms.

Interventional radiology has developed into a subspecialty with application in the treatment and palliation of patients with advanced malignant diseases. A directed catheter delivers high concentrations of chemotherapy directly into the tumor bed. Embolic particles may be injected to stop hemorrhage or to occlude the blood supply of a cancer, resulting in pain relief or tumor shrinkage. These techniques can be incorporated into a multidisciplinary approach to cancer.

Catheterization↗
PubMed1988

Feasibility and efficacy of weekly intraarterial cisplatin in locally advanced (stage III and IV) head and neck cancers.

Thirty-five consecutive patients with primary unresectable head and neck cancers were considered eligible for protocol treatment with neoadjuvant intraarterial cisplatin. External carotid artery catheterizations were technically feasible in 29 patients (83%). Twenty-five patients with 28 primary tumors received intraarterial cisplatin, 100 mg/m2, every seven to 14 days for three cycles. The most common toxicity was nausea and vomiting. Ipsilateral hemialopecia, transient VII nerve palsy, and blurring of vision seem to be unique to this route of administration at this dose. A complete response was seen at the primary tumor site in nine of 28 (32%), with 14 of 28 partial responses (50%). In evaluating both primary tumor and nodal disease, five of 25 patients achieved a complete response and 15 of 25 a partial response. In previous reports, one complete response was observed in 74 patients with head and neck cancer treated with neoadjuvant intravenous (IV) cisplatin every 3 weeks. The overall response of 82% reported here is comparable to that reported with combination chemotherapy and suggests an advantage to the arterial administration of cisplatin when possible in the neoadjuvant setting.

Carotid Artery, External↗
PubMed1988

Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer.

Twenty-two patients with disseminated adenocarcinoma of the large bowel received therapy with 5-fluorouracil 800-1000 mg/m2 as a 24 h infusion for 4 consecutive days with 60 mg/m2 intravenous folinic acid administered every 6 hours. Major responses were seen in 3 of 20 (15%) evaluable patients, for a median of 5 months. Mucositis was the major toxicity occurring in 80% of patients. Folinic acid resulted in an additional $960/m2 per therapeutic course without improvement of response rate or survival at this dose and schedule.

Adenocarcinoma↗
PubMed1983

High dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas.

Eleven patients with malignant gliomas recurring after surgery and radiation therapy, were treated with high dose BCNU 1 050-1 200 mg/M2 with autologous bone marrow rescue. Four patients also received concomitant 5-fluorouracil 1 000 mg/M2/24 hr daily for three days. Eight of ten evaluable patients demonstrated improvement on CAT scan as well as a decrease in steroid requirement. All patients surviving longer than two weeks after BCNU administration experienced full hematologic recovery. No delayed myelosuppression was seen after a single course of high dose therapy. Two patients died as a result of therapy, one following a second induction of BCNU for a total cumulative BCNU dose of 2 400 mg/M2 and one of infection while cytopenic. Additional toxicity includes one steroid-responsive interstitial pneumonitis, one centrilobular necrosis of the liver which spontaneously resolved and one episode of deep vein thrombosis. With limitation on the maximum BCNU dose and distribution of the total dose over three days, high dose BCNU can be administered with acceptable toxicity. This approach may offer a higher response rate than that expected for standard dose BCNU.

Adult↗